{"entity":{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","aka":[],"tldr":"A phase 1/2 trial of KRT-232, Acalabrutinib in diffuse large b-cell lymphoma and hodgkin lymphoma, run by Kartos Therapeutics, Inc., now recruiting.","summary":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL is a phase 1/2 interventional study registered as NCT04502394 by Kartos Therapeutics, Inc., with 84 participants planned, started 2021-02-23 and due to reach its primary completion in 2022-10. Interventions recorded: KRT-232, acalabrutinib. Conditions listed: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04502394","url":"https://clinicaltrials.gov/study/NCT04502394"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl","hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["krt-232","acalabrutinib"],"companies":["kartos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04502394","phase":"1/2","setting":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia","sponsor":"Kartos Therapeutics, Inc.","enrolled":84,"outcomes":[]},"route":"/trials/nct04502394/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/"}],"company":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/"}]}}